MedPath

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
Registration Number
NCT00036101
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with acute symptoms of Bipolar Disorder

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Local Institution

πŸ‡ΊπŸ‡Έ

Bellevue, Washington, United States

Local Institution
πŸ‡ΊπŸ‡ΈBellevue, Washington, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.